Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cyclin D1 G870A polymorphism: Association with uterine leiomyoma risk and in silico analysis.

Salimi S, Shahrakipour M, Hajizadeh A, Mokhtari M, Mousavi M, Teimoori B, Yaghmaei M.

Biomed Rep. 2017 Feb;6(2):237-241. doi: 10.3892/br.2016.830. Epub 2016 Dec 21.

2.

Cyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation.

Núñez KG, Gonzalez-Rosario J, Thevenot PT, Cohen AJ.

Ochsner J. 2017 Spring;17(1):56-65.

3.

Aberrant expression of cyclin D1 in cancer.

Inoue K, Fry EA.

Sign Transduct Insights. 2015;4:1-13. doi: 10.4137/STI.S30306. Epub 2015 Sep 20.

4.

Investigation of cyclin D1 rs9344 G>A polymorphism in colorectal cancer: a meta-analysis involving 13,642 subjects.

Qiu H, Cheng C, Wang Y, Kang M, Tang W, Chen S, Gu H, Liu C, Chen Y.

Onco Targets Ther. 2016 Oct 27;9:6641-6650. eCollection 2016.

5.

Association between cyclin D1 (CCND1) G870A polymorphism and gastric cancer risk: a meta-analysis.

Zhang Y, Zeng X, Lu H, Ji H, Zhao E, Li Y.

Oncotarget. 2016 Oct 4;7(40):66109-66118. doi: 10.18632/oncotarget.11848.

6.

Genetic susceptibility to Barrett's oesophagus: Lessons from early studies.

Findlay JM, Middleton MR, Tomlinson I.

United European Gastroenterol J. 2016 Aug;4(4):485-92. doi: 10.1177/2050640615611018. Epub 2015 Oct 13. Review.

7.

Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis.

Luo T, Chen J, Liu JJ, Li H, You XM, Wang HL, Zhu SL, Li LQ.

Onco Targets Ther. 2016 Jul 21;9:4483-9. doi: 10.2147/OTT.S108754. eCollection 2016.

8.

CCND1 G870A polymorphism and colorectal cancer risk: An updated meta-analysis.

Xu XM, Ni XB, Yang GL, Luo ZG, Niu YM, Shen M.

Mol Clin Oncol. 2016 Jun;4(6):1078-1084. Epub 2016 Apr 4.

9.
10.

Polymorphisms of cell cycle regulator genes CCND1 G870A and TP53 C215G: Association with colorectal cancer susceptibility risk in a Malaysian population.

Zahary MN, Ahmad Aizat AA, Kaur G, Yeong Yeh L, Mazuwin M, Ankathil R.

Oncol Lett. 2015 Nov;10(5):3216-3222. Epub 2015 Sep 18.

11.

CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.

Xue Y, Rong L, Tong N, Wang M, Zhang Z, Fang Y.

Int J Clin Exp Pathol. 2015 Sep 1;8(9):11594-600. eCollection 2015.

12.

Association of CCND1 gene polymorphism with cervical cancer susceptibility in Caucasian population: a meta-analysis.

Yang M, Zhu H, Hu T, Liu S, Wang H.

Int J Clin Exp Med. 2015 Aug 15;8(8):12983-8. eCollection 2015.

13.

Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells.

Kim YC, Chen C, Bolton EC.

PLoS One. 2015 Sep 15;10(9):e0138286. doi: 10.1371/journal.pone.0138286. eCollection 2015.

14.

Cyclin D1 G870A polymorphism and glioma risk in a Chinese population.

Liu H, Song Z, Liao DG, Zhang TY, Liu F, Zheng W, Luo K, Yang L.

Int J Clin Exp Med. 2015 Jun 15;8(6):9991-5. eCollection 2015.

15.

SAM68: Signal Transduction and RNA Metabolism in Human Cancer.

Frisone P, Pradella D, Di Matteo A, Belloni E, Ghigna C, Paronetto MP.

Biomed Res Int. 2015;2015:528954. doi: 10.1155/2015/528954. Epub 2015 Jul 26. Review.

16.

Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response.

Corkery DP, Holly AC, Lahsaee S, Dellaire G.

Nucleus. 2015;6(4):279-88. doi: 10.1080/19491034.2015.1062194. Epub 2015 Jun 22. Review.

17.

Targeting cell cycle regulators in hematologic malignancies.

Aleem E, Arceci RJ.

Front Cell Dev Biol. 2015 Apr 9;3:16. doi: 10.3389/fcell.2015.00016. eCollection 2015. Review.

18.

Effect of the CCND1 A870G polymorphism on prostate cancer risk: a meta-analysis of 3,820 cases and 3,825 controls.

Zheng M, Wan L, He X, Qi X, Liu F, Zhang DH.

World J Surg Oncol. 2015 Feb 15;13:55. doi: 10.1186/s12957-015-0479-8.

19.

Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors.

Bendris N, Lemmers B, Blanchard JM.

Cell Cycle. 2015;14(12):1786-98. doi: 10.1080/15384101.2014.998085. Review.

20.

Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Peyressatre M, Prével C, Pellerano M, Morris MC.

Cancers (Basel). 2015 Jan 23;7(1):179-237. doi: 10.3390/cancers7010179. Review.

Supplemental Content

Support Center